Immunotherapy with depigmented glutaraldehyde‐polymerized extracts: changes in quality of life

Abstract

In [1], on page 574, the text of the second paragraph has a mistake (in bold): ''Two vials were prepared to be used as a therapeutic vaccine. Vial no. 2 contained 270 mg of D. glomerata and 280 mg of O. europaea, which were the result of depigmenting and polymerizing 100 HEP L , corresponding to 750 mg of freeze-dried extract of D. glomerata (60 mg/mL Dac g 2, 20 mg/mL Dac g 115) and 3550 mg of freeze-dried extract of O. europaea (131 mg/mL Ole e 1). Vial no. 1 was a 10-fold dilution of vial no. 2.''The correct text is ''Two vials were prepared to be used as a therapeutic vaccine. Vial no. 2 contained 270 mg of D. glomerata and 280 mg of O. europaea, which were the result of depigmenting and polymerizing 1000 HEP L , corresponding to 750 mg of freeze-dried extract of D. glomerata (60 mg/mL Dac g 2, 20 mg/mL Dac g 115) and 3550 mg of freeze-dried extract of O. europaea (131 mg/mL Ole e 1). Vial no. 1 was a 10-fold dilution of vial no.2.''

Efficacy, safety, and immunological effects of a 2‐year immunotherapy with Depigoid® birch pollen extract: a randomized, double‐blind, placebo‐controlled study

“…The size of response to treatment seen in our study is comparable with that noted in previous studies of immunotherapy with unmodified birch pollen extract [9, 10, 32, 33]. This is the first study to report improvement in rhinitis QOL scores following immunotherapy with a depigmented polymerized birch pollen extract, although this has been reported for patients sensitive to grass pollens and HDM [20, 22]. Of note, some of these studies did show significant reductions in symptom scores, which was not observed in our study.…”

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal allergic asthma

“…Although we did not compare the results in the different treatment arms with a pure placebo group, we were able to answer our original research question, which was to demonstrate the superiority of the combined treatment over SIT alone. Anyway, the superiority of these both treatment options over placebo has already been shown in previous reports [17–20, 31–33]. There are now several open‐label studies which have shown that SIT also lowers the onset of new sensitization and the progression from allergic rhinoconjunctivitis to bronchial asthma [34, 35].…”

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

“…Clinical efficacy (reduction of symptoms and/or need for medications) has been confirmed with grass (1102,1104,(1650)(1651)(1652)(1653)(1654)(1655), birch (1650,1651,(1656)(1657)(1658)(1659), ragweed (1660), Russian thistle (1661), Parietaria pollen (1662,1663), mites (1664)(1665)(1666)(1667)(1668)(1669) and cat (1670). It should be noted that three of the studies (1104,1660,1670) clearly demonstrated that the clinical effect is dose dependent.…”